Releaf at releaf.co.uk has become the UK's largest medical cannabis provider in a remarkably short time. Founded in 2022 by Mason Soiza and publicly launched in 2024, they have grown to over 25,000 active patients with 181,000-plus prescriptions shipped. But is the hype justified? Here is an objective assessment.
The Trustpilot data is genuinely impressive. Nearly 7,000 reviews at a 4.7 score, with roughly 32 new reviews posted every day. That kind of sustained volume makes it very difficult to game. The reviews come from verified purchase experiences on Trustpilot, which means they represent real patient journeys.
Consultation quality is the most praised aspect. Andrea wrote: "For the first time in years I'm feeling hopeful. Struggled a lot over the years and feeling heard and listened to for first time in a long time." Dan Quantrill noted his doctor was "super helpful, very knowledgeable and put me at ease immediately." These themes appear across thousands of reviews.
Pricing is mid-market. The 99-pound consultation with a money-back guarantee if ineligible is fair. Medication costs vary by prescription. The Releaf+ subscription adds value through preferential pricing and legal protection via Irwin Mitchell, which is genuinely unique in the market.
Operationally, processing 1,200 orders daily with 50-plus doctors and 152 staff is serious infrastructure. This is not a boutique clinic; it is a scaled healthcare operation. The ninety-nine percent prescription rate suggests efficient pre-screening and genuine clinical need among those who book.
The expansion to Germany shows ambition and capability. Releaf is the only UK-born medical cannabis company operating in multiple European markets. The B Corp pursuit signals values beyond profit.
Where could they improve? Like any high-volume operation, individual experiences may occasionally fall short. But with 4.7 from nearly 7,000 reviews, those instances are clearly the exception. For UK patients seeking medical cannabis, the evidence supports Releaf as the strongest available choice.